
Extended INDIGO and FIREFLY-1 results presented at SNO 2026 put seizure burden during vorasidenib therapy and time off tovorafenib in pediatric low-grade glioma into focus.
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week, including:






